How Does Klisyri Work? Mechanism of Action Explained in Plain English

Klisyri (tirbanibulin) is described as a "first-in-class" medication because nothing quite like it existed before for skin conditions. It attacks precancerous actinic keratosis (AK) cells using two separate mechanisms simultaneously — a dual-action approach that distinguishes it from older single-mechanism AK treatments. Here's what that means in practical terms.

What Are Actinic Keratosis Cells and Why Are They a Problem?

Actinic keratosis (AK) lesions are patches of skin where keratinocytes (the main cells of the outer skin layer) have been damaged by years of UV radiation and have become abnormal — growing too fast and resisting the natural signals that tell cells to stop dividing or die. These cells are precancerous: not yet cancerous, but on a trajectory toward squamous cell carcinoma if left untreated.

Because AK cells are growing rapidly and disorderly, they have specific vulnerabilities that normal skin cells don't. Klisyri is designed to exploit exactly those vulnerabilities.

Mechanism 1: Inhibiting Tubulin Polymerization (Blocking Cell Division)

Every time a cell divides, it needs to build a structure called the mitotic spindle — a framework made of protein strands called microtubules. Think of microtubules like a temporary scaffold that the cell assembles, uses to pull apart its chromosomes, and then dismantles. Without this scaffold, a cell literally cannot split in two.

Tirbanibulin binds directly to the colchicine-binding site of beta-tubulin — one of the proteins that assembles into microtubules. By occupying this site, it prevents tubulin from polymerizing (joining together to form the microtubule). Without functional microtubules, the cell gets stuck mid-division, which triggers a process called apoptosis — essentially programmed cell death. The precancerous cell self-destructs.

This mechanism is selective: because AK cells are dividing much faster than normal surrounding skin cells, they are far more dependent on rapid microtubule assembly and far more vulnerable to its disruption.

Mechanism 2: Inhibiting Src Kinase Signaling (Blocking Survival Signals)

The second mechanism is less intuitive but equally important. Inside every cell, there are proteins called kinases — molecular switches that turn cellular processes on and off. One family of kinases, called Src kinases (or Src tyrosine kinases), act like an "on" button for cell growth, survival, and the formation of new blood vessels.

In AK and other precancerous cells, Src kinase signaling is often overactivated — constantly telling the cell to keep growing and to resist death signals. Tirbanibulin inhibits Src kinase activity, effectively turning off these survival signals. Without them, the abnormal skin cells lose their ability to sustain themselves and are more susceptible to dying.

Why Dual Mechanism Matters

By attacking AK cells through two independent pathways at the same time, tirbanibulin creates a compounding effect. A cell that might survive one type of attack has a much harder time escaping both simultaneously. This dual-action approach is one reason Klisyri achieves meaningful clearance rates in just 5 days, while older single-mechanism treatments often require 2–12 weeks.

Is the Mechanism of Action Fully Understood?

Interestingly, the FDA prescribing information for Klisyri states that "the mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown." This is a regulatory precision point: the molecular actions of tirbanibulin in laboratory settings are well characterized, but the exact cellular sequence that leads to AK clearance in human skin hasn't been definitively proven in clinical trials. This is common in dermatology — diclofenac gel and imiquimod also carry similar caveats in their labeling.

How Klisyri Differs From Other AK Treatments Mechanistically

Fluorouracil (5-FU): A chemotherapy agent that blocks DNA synthesis in rapidly dividing cells; single mechanism; causes significant skin inflammation

Imiquimod: Stimulates the immune system (toll-like receptor 7) to attack AK cells; no direct anti-proliferative effect on cells

Diclofenac gel: NSAID; inhibits COX-2 enzyme and reduces prostaglandins that promote AK cell survival

Klisyri (tirbanibulin): Dual mechanism — directly disrupts cell division via tubulin inhibition AND suppresses survival signaling via Src kinase inhibition

Systemic Absorption: Is Klisyri Absorbed Into the Bloodstream?

Systemic absorption of Klisyri is minimal but measurable. In pharmacokinetic studies, following 5-day topical treatment of a 100 cm² area, peak plasma concentration (Cmax) was approximately 1.32 ng/mL — an extremely small amount. Plasma protein binding of tirbanibulin is 88%. Because systemic exposure is negligible, no dose adjustments are needed for patients with kidney or liver disease.

For practical information on using Klisyri, see What Is Klisyri? Uses, Dosage, and What You Need to Know. Having trouble finding Klisyri at your pharmacy? medfinder can help.